February 10, 2020 VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attn: Ada D. Sarmento

RE: Inovio Pharmaceuticals, Inc.

Registration Statement on Form S-3

Filed January 31, 2020

File No. 333-236202

Acceleration Request

Requested Date:	February 13, 2020
Requested  Time:	4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on February 13, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance. The Registrant hereby authorizes each of Brian Leaf and Jeffrey Libson of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053.

Very truly yours,

Inovio Pharmaceuticals, Inc.

/s/ Peter Kies

Peter Kies

Chief Financial Officer

cc: Brian Leaf, Cooley LLP

Jeffrey Libson, Cooley LLP